Salute e Benessere

Invitation to presentation of Essity's interim report for quarter 2, 2024

Contact information for conference call with the possibility to ask questions:UK: +44 (0) 33 0551 02 00 USA: +1 786 697 35 01SWE: +46 (0)8 505 204 24Please call in well in advance of the start of the presentation. Indicate: "Essity". Contact information for conference call with the possibility to ask questions: UK: +44 (0) 33 0551 02 00 USA : +1 786 697 35 01 SWE: +46 (0)8 505 204 24 Please call in well in advance of the start of the presentation. Indicate…
PR Newswire
18/06/2024

TICA Secures Phase II Contract with Dubai HMS Mirdif Hospital

Mirdif Luxury Hospital, a premier medical institution in Dubai and the Middle East, known for its cutting-edge technology and premium services, is expanding through its Phase II project. The addition includes specialty wards and top-tier operating rooms. Prioritizing stringent environmental and air quality standards, the hospital conducted a thorough selection process for its equipment. TICA, recognized for its advanced technology and superior products, secured the contract, ensuring the…
PR Newswire
18/06/2024

ONWARD® Medical to Highlight Brain-Computer Interface at HLTH Europe Conference

CEO Dave Marver and trial participant Gert-Jan Oskam will discuss ONWARD ARC-BCI™ Therapy during main stage presentation CEO Dave Marver and trial participant Gert-Jan Oskam will address conference attendees in a keynote on the main stage on June 19, 2024. The pair will discuss how investigational ARC-BCI Therapy uses artificial intelligence to enable thought-driven movement after paralysis, the future of therapies to treat SCI, and Gert-Jan's experience as the first human to be implanted...
Nasdaq GlobeNewswire
18/06/2024

Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund…

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on June 19, 2024, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release. Funding underpins the advancement of AGAMREE® (vamorolone) roll-out and growth in Europe and the pursuit of further developmental initiatives Financing includes up to USD 38 million from R-Bridge, an affiliate of CBC Group, in exchange for a partial monetization of royalty payments received by Santhera in...
Nasdaq GlobeNewswire
18/06/2024

INCONTINENT? INTIMINA HAS A PLUMBER FOR THAT

During this time Stopcocks Women Plumbers will be fixing household leaks, having honest conversations about incontinence, and gifting customers INTIMINA's pelvic floor training device - KegelSmart 2. During this time Stopcocks Women Plumbers will be fixing household leaks, having honest conversations about incontinence, and gifting customers INTIMINA's pelvic floor training device - KegelSmart 2. Hattie Hasan MBE, Stopcocks Founder adds: " We deal with women's leaks daily, because our...
PR Newswire
18/06/2024

NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical…

NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the USAarhus, Denmark, 18 June 2024– NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with severe neuromuscular diseases, today announces that it has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 2...
Nasdaq GlobeNewswire
18/06/2024

EUROAPI and Priothera enter into CDMO collaboration to advance oncology project

Press Release EUROAPI and Priothera, a biotechnology company specializing in the treatment of hematological malignancies and the improvement of CAR-T cell therapies, have signed a 5-year CDMO agreementEUROAPI will develop and industrialize the manufacturing process of innovative complex molecule for blood cancersParis – June 18, 2024– EUROAPI announces today the implementation of a 5-year development and manufacturing agreement with Priothera, a...
Nasdaq GlobeNewswire
18/06/2024

CARBIOS and TOMRA Textiles join forces to scale circularity of polyester…

CARBIOS and TOMRA Textiles will collaborate to close the textiles circularity gap between collection of textile waste and innovative technologies for textile-to-textile recyclingOslo/Clermont-Ferrand, Tuesday 18 June 2024 (6.45am CEST):CARBIOS (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, andTOMRA Textiles, a tech venture set up by sorting technology leaderTOMRA...
Nasdaq GlobeNewswire
18/06/2024

Pfizer's Setback in Duchenne Muscular Dystrophy Treatment Trial Clears Path for…

According to DelveInsight's estimates, the US accounted for around ~17K total prevalent cases of Duchenne muscular dystrophy in 2023. The highest cases were found in the children of the 5-9 age group, these numbers are expected to grow by the year 2034. According to DelveInsight's estimates, the US accounted for around~17Ktotal prevalent cases of Duchenne muscular dystrophy in 2023. The highest cases were found in the children of the5-9 age group, these numbers are expected to grow by...
PR Newswire
17/06/2024

RECOMMENDED CASH OFFER for MARIADB PLC by MERIDIAN BIDCO LLC which is an…

MANHATTAN BEACH, Calif., June 17, 2024 /PRNewswire/ -- On 24 May 2024, Meridian Bidco LLC ("Bidco") made an offer to acquire the entire issued and to be issued share capital of MariaDB plc ("MariaDB") (the "Offer") with the terms and conditions of the Offer set out in the offer document despatched and filed by Bidco as Exhibit (a)(1)(A) to the Tender Offer Statement filed on Schedule TO with the US Securities and Exchange Commission on 24 May 2024 (the "Offer…
PR Newswire
17/06/2024

GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+®…

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024-GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusion of NIS2+® as a key tool for detecting at-risk MASH 1in the European Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). The...
Nasdaq GlobeNewswire
17/06/2024

Global Omega-3 Pet Supplement Sales Set to total USD 2,292.5 million by 2034…

Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-19711 Download the Sample PDF report to explore key market insights and trends:https://www.futuremarketinsights.com/reports/sample/rep-gb-19711 The humanization of pets drives the global omega-3 pet supplement industry forward. People want good health for their pets. Pet owners purchase supplements to ensure their pets receive the proper nutrition and...
PR Newswire
17/06/2024

The era of biosolutions. Outlook upgraded for 2024

Novonesis is performing very well and the 2024 outlook for pro forma organic sales growth is now expected at the upper end of the 5-7% range while the pro forma adjusted EBITDA margin is increased to 35-36%. Novonesis' Capital Markets Day on June 18, 2024 will provide an introduction to Novonesis with insights on how the company intends to capture and accelerate organic sales growth. Also, Novonesis maintains the target for organic sales growth at 6-8% CAGR through 2025 with an adjusted...
Nasdaq GlobeNewswire
17/06/2024

Surgical Suction Instruments Market to Hit USD 503 Million by 2029, Driven by…

Browse in-depth TOC on "Surgical Suction Instruments Market" Browse in-depth TOC on "Surgical Suction Instruments Market" 390 - Tables 300 - Figures400 - Pages Surge in Surgical Procedures Fuels Demand for Suction Instruments The escalating number of surgeries globally serves as a prime catalyst for the surgical suction instruments market. With surgeries on the rise, the demand for these vital tools intensifies, ensuring optimal surgical conditions, minimizing...
PR Newswire
17/06/2024

Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine…

First regulatory submission completed for CHIKV VLP seeking approval of the vaccine candidate for immunization against chikungunya virus infection in individuals 12 years of age and olderRepresents first BLA for a chikungunya vaccine for adolescentsCOPENHAGEN, Denmark, June 17, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the rolling submission process which was initiated in April 2024 with the U.S. Food and Drug Administration (FDA) for a Biologics License...
Nasdaq GlobeNewswire
17/06/2024

Dental 3D Printing Materials Market to be Worth $5.4 Billion by 2031 - Exclusive…

Dental laboratories use 3D printers to produce crowns and bridges, orthodontic models, surgical guides, aligners, castable restorations, and others. As the manual model-making process is time-consuming, 3D printing allows multiple products to be printed simultaneously with higher accuracy. Dental laboratories use 3D printers to produce crowns and bridges, orthodontic models, surgical guides, aligners, castable restorations, and others. As the manual model-making process is time-consuming, 3D...
PR Newswire
17/06/2024

Membrane Chromatography Market to Reach USD 637 Million with 14.7% CAGR |…

Browse in-depth TOC on "Membrane Chromatography Market"416 - Tables52 - Figures348 - Pages Browse in-depth TOC on "Membrane Chromatography Market" 416 - Tables 52 - Figures 348 - Pages DRIVER: Catalyzing Growth Through Increased Biopharmaceutical R&D As C-level executives, you're aware of the pivotal role R&D plays in the biopharmaceutical sector, especially amidst the escalating demand for treatments targeting chronic illnesses. The robust increase in R&D...
PR Newswire
17/06/2024

Renowned Public Health Expert Prof. Siegal Sadetzki Joins Briya

With Prof. Sadetzki joining the Briya team and helping design data cleansing and medical evaluation processes, life science companies can be assured that the data they receive is of the highest quality, providing a comprehensive view of the patient journey. This enables them to expedite research timelines, obtain more accurate results, allocate resources more efficiently for clinical studies, and develop data-driven market strategies. With Prof. Sadetzki joining the Briya team and helping...
PR Newswire
17/06/2024

PRADA SPRING/SUMMER 2025 MENSWEAR SHOW

To view the Multimedia News Release, please click: https://www.multivu.com/players/uk/9275551-prada-spring-summer-2025-menswear-show/ To view the Multimedia News Release, please click: https://www.multivu.com/players/uk/9275551-prada-spring-summer-2025-menswear-show/ **FACE** Alexander enhances skin with Prada Skincare, employing Prada Augmented Skin The Essence as a first step. This transformative 2-in-1 toner and micro-peel essence optimizes and renews skin texture while gently...
PR Newswire
17/06/2024

CardioFlow's VitaFlow Liberty™ Granted EU CE-MDR Mark, Advancing Global…

CardioFlow, one of the world's leading innovative medical device companies, has entered the field of structural heart disease when the field was still at an early adoption phase. Originating and headquartered in Shanghai, China, CardioFlow was listed on the Hong Kong Stock Exchange on February 2021. The company has a diverse product pipeline resulting from independent and collaborative research, covering structural heart devices such as transcatheter aortic, mitral, and tricuspid valves, left…
PR Newswire
17/06/2024

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 17, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from June 10, 2024, to June 14, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)...
Nasdaq GlobeNewswire
17/06/2024

Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of…

The license includes 5 new patent families that were just filed in 2023 and hence have their full potential patent life ahead of them. The technologies include enhanced versions of dendritic cells (DCs) and DC based therapies, as well as conditioning regimens designed to enhance patient responses and approaches to reprogram the tumor microenvironment to boost immune therapies and help overcome resistance to checkpoint inhibitors. The license includes 5 new patent families that were just filed...
PR Newswire
17/06/2024

iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug…

“With the initiation of the first Phase 3 study for belrestotug, we are entering a monumental stage in our journey to develop a world-leading oncology company. Nearly 70% of patients with first-line PD-L1 high non-small cell lung cancer rely upon a chemotherapy-free regimen. We believe belrestotug + dostarlimab are poised to potentially advance the therapeutic regimen in this setting and establish new benchmarks,” said Michel Detheux, Ph.D., president and chief executive officer of iTeos...
Nasdaq GlobeNewswire
17/06/2024

Curium Continues to Make Strong Progress in European Roll-Out Of PYLCLARI® –…

First doses of PYLCLARI® administered in Austria in early May 2024PYLCLARI® now available in France, Germany, Greece, Italy, and the Netherlands PARIS, June17, 2024(GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that with first doses in Austria administered in May 2024, it is making strong progress in the European roll-out of PYLCLARI ®(INN: Piflufolastat ( 18 F) also known as ( 18 F)-DCFPyL) indicated for the detection of prostate-specific membrane...
Nasdaq GlobeNewswire
17/06/2024
Altri  Comunicati